Skip Navigation

ALS News

field with sun shining

Packard Center News

Jul 28
2021
ALS Headlines, Breaking Research, Packard Center News
Packard researchers used Answer ALS cell lines to show that the protein CHMP7 accumulates in the nucleus, triggering a series of events that creates some of the molecular hallmarks found in both sporadic and familial ALS as well as FTD.
Jun 22
2021
ALS Headlines, Packard Center News
Using AI to leverage the data in healthcare organisations will have a positive impact on both patient care and internal efficiencies.
Read the full article on www.informationage.com:
Jun 17
2021
ALS Headlines, Packard Center News
Administered by Kaggle, the End ALS Challenge asked participants to help identify solutions to the disease.
Jun 14
2021
ALS Headlines, Packard Center News, Research Bytes
A team of Packard-funded scientists, led by Udai Pandey and Chris Donnelly at the University of Pittsburgh, have identified a new mechanism through which mutant FUS can lead to ALS
Jun 14
2021
ALS Headlines, Packard Center News
Teams from the University of Maryland and Harvard University have showed that ALS-linked mutations in UBQLN2 compromise import of proteins in large clumps in the cytoplasm.
Mar 19
2021
ALS Headlines, Packard Center News
Answer ALS Partners to Launch the 'End ALS Challenge' Digital Competition
Jan 8
2021
ALS Headlines, Breaking Research, Packard Center News
The Answer ALS data portal seeks to empower researchers around the globe with the data needed to finally answer ALS.
To see the video tribute
Nov 9
2020
Packard Center News, Research Bytes
In a new study, Packard researcher Jiou Wang and colleagues have identified a new regulatory switch for protein quality control that plays a role in the development of ALS.
Click here to read the full study:
Sep 14
2020
ALS Headlines, Packard Center News
In a new study, a team of Packard scientists identified a key intersection between two major pathways of pathology in ALS and frontotemporal dementia (FTD)
Read the full article in Science Translational Medicine
Sep 3
2020
ALS Headlines, Packard Center News
Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment with the drugs sodium phenylbutyrate and taurursodiol, combined together, could significantly slow functional decline over 24 weeks compared to placebo.
Read more about the trial in a recent article on www.nytimes.com